Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Use Luminex s xMAP Platform in IVD Development

NEW YORK, Jan. 10 (GenomeWeb News) - Luminex will provide access to PerkinElmer to its xMAP technology and assay-development capabilities, PerkinElmer said today.

 

Under the agreement, PerkinElmer will standardize its multiplex assay development on the xMAP platform. The company will use the technology in biomarker panels for pharmaceutical development and ADME/Tox, and to develop in vitro diagnostics in maternal, neonatal, and prenatal health.

 

Additional details were not disclosed.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.